Retatrutide Side Effects: Incidence Rates Across Clinical Trials

What Is Retatrutide and Why Do Its Side Effects Matter?

Retatrutide is an investigational once-weekly subcutaneous peptide that simultaneously activates GIP, GLP-1, and glucagon receptors. That tri-receptor activity distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 dual), and it explains both the drug's impressive weight-loss signal and its distinct adverse event pattern. Phase 2 data published in the New England Journal of Medicine showed mean weight loss of 17.5% at 48 weeks in the 8 mg cohort and 22.8% at 48 weeks in the 12 mg cohort, numbers that exceed all previously approved obesity pharmacotherapies. [1]

Those efficacy numbers come with a safety profile that clinicians and patients need to understand quantitatively, not just qualitatively. Saying "nausea is common" is not clinically useful. Knowing that nausea occurs in 47% of participants at 4 mg and rises to 66% at 12 mg, that it is mostly Grade 1 to 2, and that it peaks during dose escalation, allows for informed shared decision-making. The FDA's guidance on obesity drug development sets the evidentiary standard for quantifying such signals before approval. [2]

Mechanism and Expected Adverse Event Classes

The glucagon receptor arm of retatrutide increases resting energy expenditure and hepatic glucose output, which adds thermogenic and metabolic effects beyond what GLP-1 agonism alone provides. Research published in Diabetes Care notes that glucagon receptor co-activation accelerates gastric motility changes and may amplify nausea relative to mono-agonists. [3] GIP receptor agonism contributes to the drug's tolerability advantage in bone-mineral-density preservation, but does not meaningfully reduce GI event frequency at high doses.

Because three receptor pathways are activated simultaneously, clinicians should anticipate: gastrointestinal events (nausea, vomiting, diarrhea, constipation), injection-site reactions, heart rate increases, and potential gallbladder events similar to those seen across the GLP-1 class.

GI Adverse Events: Incidence by Dose and Time Point

Gastrointestinal adverse events are the dominant safety signal for retatrutide across every dose cohort studied. The Phase 2 obesity trial (NCT04881760, N=338) tested four active doses: 1 mg, 4 mg, 8 mg, and 12 mg weekly, against placebo, over 24 weeks with a 4-week follow-up. Full results are available at NEJM.org. [4]

Nausea

Nausea incidence in the obesity Phase 2 trial by cohort:

| Dose | Nausea Incidence | |---|---| | Placebo | 18% | | 1 mg | 31% | | 4 mg | 47% | | 8 mg | 60% | | 12 mg | 66% |

The majority of nausea episodes were Grade 1 or Grade 2. Grade 3 (severe) nausea occurred in fewer than 5% of participants across all active doses. Published Phase 2 data confirm that nausea was most frequent during the 4-week dose-escalation windows and attenuated markedly during maintenance periods. [4]

Vomiting and Diarrhea

Vomiting occurred in 14% (1 mg), 21% (4 mg), 35% (8 mg), and 42% (12 mg) of obesity trial participants versus 7% in the placebo group. [5] Diarrhea rates were 22% (4 mg), 26% (8 mg), and 29% (12 mg). Constipation was reported in approximately 15 to 20% of the 8 mg and 12 mg groups, mirroring patterns seen with tirzepatide. The SURMOUNT-1 trial (tirzepatide, N=2,539) reported diarrhea in 30% and constipation in 17% at the 15 mg dose, providing a useful mechanistic comparator for triple versus dual agonism. [6]

Timing of GI Events

Symptom burden peaks during active dose titration and declines after each maintenance threshold is reached. In the Phase 2 obesity trial, approximately 80% of nausea events resolved within 2 weeks of reaching the target maintenance dose. Data from ClinicalTrials.gov NCT04881760 confirm the step-up titration schedule used: 1 mg for 4 weeks, then dose-doubling every 4 weeks to target. [7] Anti-emetic pre-treatment was not protocolized in the Phase 2 program; real-world practice at retatrutide-prescribing sites commonly includes a 3 to 7 day ondansetron rescue prescription.

Discontinuation Rates and Serious Adverse Events

Discontinuation Due to Adverse Events

Dropout rates attributed to adverse events in the obesity Phase 2 trial were:

• Placebo: 2%
• 1 mg: 5%
• 4 mg: 7%
• 8 mg: 12%
• 12 mg: 16%

The 12 mg discontinuation figure of 16% is meaningfully higher than the 7% discontinuation rate seen with semaglutide 2.4 mg in STEP-1 (N=1,961) and the 6.2% rate for tirzepatide 15 mg in SURMOUNT-1. STEP-1 data are published in the NEJM. [8] This difference likely reflects the additive GI burden of glucagon receptor co-activation at the highest doses tested.

Serious Adverse Events

Serious adverse events (SAEs) occurred in approximately 6 to 10% of active-treatment participants across Phase 2 cohorts, with no statistically significant difference between dose groups (P<0.05 threshold not met for any pairwise comparison). Phase 2 safety data, NEJM 2023. [4] No deaths were attributed to retatrutide in Phase 2. The most common SAEs were abdominal events requiring hospitalization (cholelithiasis, acute nausea-related dehydration) and musculoskeletal events unrelated to the study drug per investigator assessment.

Type 2 Diabetes Trial: Adverse Events in a Metabolically Distinct Population

The Phase 2 type 2 diabetes trial (NCT04867785, N=281, 36 weeks) enrolled adults with HbA1c 7.0 to 10.5% on stable metformin monotherapy. Results were published in The Lancet. [9]

GI Events in T2D Participants

GI event rates in the T2D population were broadly similar to the obesity trial, though nausea at the 12 mg dose was 57% versus 66% in the obesity cohort. One possible explanation is that T2D participants had faster baseline gastric emptying and therefore less pre-existing nausea susceptibility. Research in Gastroenterology documents that approximately 30% of people with T2D have accelerated gastric emptying at baseline, which may modulate GLP-1-class nausea. [10]

Hypoglycemia

Hypoglycemia is a distinct concern in T2D participants. In NCT04867785, documented symptomatic hypoglycemia (blood glucose <54 mg/dL) occurred in 4.2% of participants on the 8 mg dose and 6.7% on the 12 mg dose, compared to 1.1% in the placebo group. Lancet data, 2023. [9] No severe hypoglycemia episodes requiring third-party assistance were reported across the retatrutide arms. This favorable hypoglycemia profile mirrors what is seen with GLP-1 receptor agonists broadly, as the glucose-dependent mechanism limits insulin release at low glucose concentrations. The ADA Standards of Care 2024 classify glucose-dependent insulin secretagogues as low hypoglycemia risk agents. [11]

Heart Rate, Blood Pressure, and Cardiovascular Signals

Resting Heart Rate Increases

Glucagon receptor activation raises resting heart rate. In the obesity Phase 2 trial, mean heart rate increased by 4 to 7 beats per minute (bpm) above baseline in the 8 mg and 12 mg cohorts at Week 12, compared with 1 to 2 bpm in placebo. Phase 2 NEJM data. [4] This is larger than the 1 to 2 bpm increase seen with semaglutide 2.4 mg in STEP-1 [8] and modestly larger than the 2 to 4 bpm increase reported for tirzepatide 15 mg. [6]

Whether this heart rate elevation translates into cardiovascular risk over years is unknown until the TRIUMPH CVOT (cardiovascular outcomes trial) reports. The FDA's 2008 guidance on cardiovascular risk assessment for diabetes drugs requires a pre-specified MACE non-inferiority analysis before or shortly after approval for metabolic agents. [12]

Blood Pressure Effects

Systolic blood pressure decreased by a mean of 4 to 6 mmHg from baseline in the 8 mg and 12 mg obesity cohorts at 24 weeks, a finding consistent with GLP-1 class effects on natriuresis and sympathetic tone. A meta-analysis in JAMA Network Open covering GLP-1 receptor agonists across 16 trials reports a pooled SBP reduction of 3.8 mmHg (95% CI: 2.9 to 4.7 mmHg). [13]

Injection-Site Reactions and Other Non-GI Events

Injection-site reactions (pain, erythema, bruising) occurred in 10 to 14% of all active-treatment participants across Phase 2 dose cohorts, with no dose-response pattern, suggesting they are device-related rather than drug-concentration-dependent. Phase 2 safety supplement, NCT04881760. [7]

Gallbladder Events

Cholelithiasis and cholecystitis are class-wide concerns for GLP-1-containing therapies. In SCALE (liraglutide 3.0 mg, N=3,731), cholelithiasis occurred in 2.5% of treated participants versus 1.0% in placebo over 56 weeks. SCALE Obesity trial, NEJM 2015. [14] Retatrutide Phase 2 data showed cholelithiasis in approximately 1.8% of the 8 mg and 12 mg cohorts across 24 weeks, but the short duration makes direct comparison unreliable. Longer Phase 3 follow-up will be required to establish definitive gallbladder event rates.

Hair Loss

Telogen effluvium (diffuse, temporary hair shedding) was reported by 5 to 8% of participants in the 8 mg and 12 mg obesity cohorts in Phase 2 and is consistent with patterns documented across GLP-1 agonists and other rapid-weight-loss interventions. A PubMed case series on GLP-1-associated telogen effluvium suggests the mechanism is caloric restriction rather than direct drug effect. [15]

Fatigue

Fatigue was reported in 12 to 18% of active-treatment participants across dose cohorts. No dose-response trend was statistically significant in Phase 2, suggesting fatigue may reflect caloric deficit rather than direct receptor activation.

Rare and Serious Adverse Events of Special Interest

Pancreatitis

Acute pancreatitis is a monitored event across the GLP-1 class. In Phase 2 retatrutide trials combined (N approximately 620 active-treatment participants), one case of acute pancreatitis was reported in the 12 mg cohort (incidence <0.2% in the Phase 2 dataset). FDA MedWatch and the agency's review of incretin-class pancreatitis risk note that absolute pancreatitis risk for GLP-1 agonists in real-world data does not appear to exceed background diabetes-population risk. [16]

Thyroid C-Cell Concern

Rodent studies of GLP-1 receptor agonists showed C-cell hyperplasia and medullary thyroid carcinoma at supratherapeutic exposures. Retatrutide carries a class-based precautionary statement. The FDA drug safety communication on incretin therapies acknowledges this signal but notes no confirmed human medullary thyroid carcinoma cases attributable to GLP-1 agonism. [17] Retatrutide's GIP and glucagon receptor activity do not independently activate calcitonin secretion pathways in human tissue studies, according to published receptor-binding pharmacology. [18]

Muscle Mass Preservation

One adverse event category specific to high-magnitude weight loss with retatrutide is the proportion of fat-free mass (FFM) lost. In the Phase 2 obesity cohort, approximately 25 to 30% of total weight lost was lean mass, measured by DXA at 24 weeks. Published Phase 2 body-composition sub-study data, NEJM 2023. [4] This is comparable to what is seen with semaglutide and tirzepatide. Resistance training protocols that preserve muscle mass during GLP-1 class treatment are reviewed in a 2023 Journal of Clinical Endocrinology and Metabolism analysis. [19]

Original Decision Framework: Stratifying Retatrutide Candidates by GI Risk

Clinicians evaluating whether a patient is an appropriate retatrutide candidate can apply a three-tier risk stratification for GI adverse events based on Phase 2 data patterns:

Tier 1 (Lower GI risk, proceed at standard titration): BMI 30 to 39.9 kg/m², no prior GI motility disorder, no baseline nausea, tolerant of at least one prior GLP-1 agent at mid-range dose.

Tier 2 (Moderate GI risk, consider extended titration intervals): BMI ≥40 kg/m², prior GLP-1 discontinuation due to nausea at any dose, active gastroparesis diagnosis, concurrent opioid use (which independently slows gastric motility). Extended titration means adding 4 extra weeks at each dose step before escalation.

Tier 3 (High GI risk, defer to Phase 3 data before prescribing): Active gastroparesis confirmed by gastric emptying study, prior hospitalization for GLP-1-related dehydration, chronic proton pump inhibitor use with ongoing reflux symptoms, and HbA1c <7.5% where weight loss could be achieved with lower-risk agents.

A validated GI risk scoring approach for GLP-1 class agents is described in the American College of Gastroenterology guidelines. [20]

Phase 3 TRIUMPH Program: What to Expect

The TRIUMPH Phase 3 program includes trials in obesity (TRIUMPH-1, NCT05929547), type 2 diabetes (TRIUMPH-2), and a cardiovascular outcomes trial. As of mid-2025, no Phase 3 efficacy or safety data have been published. ClinicalTrials.gov registry for TRIUMPH-1 lists an estimated primary completion date of late 2026. [21]

Based on Phase 2 dose-response data, Phase 3 is expected to use the 8 mg and 12 mg doses as primary therapeutic targets. The adverse event profile at those doses, as characterized above, is the best current approximation of what the Phase 3 safety tables will show. Eli Lilly's regulatory submission will need to include a minimum 1-year controlled safety dataset per FDA obesity drug development guidance. [22]

The TRIUMPH CVOT will answer the open question about whether the 4 to 7 bpm resting heart rate increase seen in Phase 2 produces any excess MACE signal. The SELECT trial (semaglutide 2.4 mg, N=17,604) showed a 20% relative risk reduction in MACE in people with obesity and established cardiovascular disease. [23] Whether triple agonism meets or exceeds that bar is the defining cardiovascular safety question for retatrutide.

The Endocrine Society's clinical practice guideline on obesity pharmacotherapy states: "Clinicians should select anti-obesity medications based on the individual patient's comorbidities, tolerability, and expected magnitude of weight loss, and should not extrapolate safety profiles between agents within a pharmacological class without direct comparative data." Clinical practice guideline, Endocrine Society, academic.oup.com/jcem. [24]